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Abstract: Polymer-peptide conjugates are a promising class of compounds, where 
polymers can be used to overcome some of the limitations associated with peptides 
intended for therapeutic and/or diagnostic applications. Linear polymers such as 
poly(ethylene glycol) can be conjugated through terminal moieties and have therefore 
limited loading capacities. In this research, functionalised linear poly(ethylene glycol)s are 
utilised for peptide conjugation, to increase their potential loading capacities. These 
poly(ethylene glycol) derivatives are conjugated to peptide sequences containing 
representative side-chain functionalised amino acids, using different conjugation 
chemistries, including copper-catalysed azide-alkyne cycloaddition, amide coupling and 
thiol-ene reactions. Conjugation of a sequence containing the RGD motif to poly(allyl 
glycidyl ether) by the thiol-ene reaction, provided a conjugate which could be used in 
platelet adhesion studies. 
OPEN ACCESS
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1. Introduction 
Peptides have the potential to be excellent therapeutic and targeting moieties, however their clinical 
use is limited by their lack of bioavailability, short plasma half-life due to rapid clearance through 
kidneys, poor stability as a result of enzymatic degradation and potential immunogenicity [1,2]. 
Effective solutions to improve the delivery and/or pharmacokinetic and pharmacodynamic properties 
of therapeutic peptides have been sought. Among them, the conjugation to polymers has resulted in 
multiple applications, not limited to clinical products [3], combining the advantages of these two classes 
of macromolecules [4]. Several polymer conjugates of low molecular weight drugs [5], peptides [3–8] 
and other macromolecules [9–11] based on water-soluble polymers have been developed.  
Polyethylene glycol (PEG) in particular has been successfully exploited to improve the solubility, 
stability and prevent the toxicity of its cargoes, notably peptides [12,13] and proteins [10]. First and 
second generation PEGs, based on a linear backbone, are inherently characterised by a low loading 
capacity. The latter can be increased by the generation of more complex structures, for example, PEG 
dendrimers and multi-arm PEGs such as star-PEGs. Another option is to polymerise an epoxide 
monomer yielding a linear polyether backbone reminiscent of PEG, but containing a functional group 
allowing the conjugation of the cargo along this backbone, or to co-polymerise this monomer with an 
unfunctionalised ethylene oxide monomer [14]. These homo- and co-polymers should maintain the 
capacity of the PEG chain to associate with two to three water molecules at each monomeric unit, a 
property which significantly contributes to the benefits imparted by PEG to biopharmaceutical agents, 
but also allow the conjugation of multiple copies of this agent through the repeating functional group. 
Among the functionalised epoxide monomers, allyl glycidyl ether is particularly attractive for the 
generation of multi-functional PEGs. Indeed, it is not only a protected precursor for the synthesis of 
linear polyglycerols, which can be modified after polymerisation at the hydroxyl groups along the 
polyether backbone, but also the starting material to poly(allyl glycidyl ether) (PAGE) [15,16], a polymer 
which can be directly functionalised through, for example, olefin metathesis or thiol-ene chemistry [16]. 
The synthesis of PAGE homo-polymers, their functionalisation with a synthetic peptide and their 
comparison to other PEG-based structures with potential high peptide loading capacities are  
reported herein. 
2. Results and Discussion 
Short polymers were synthesised through either anionic or cationic polymerisation, by heating an 
epoxide monomer in the presence of a strong base or cationic initiator, respectively. The length of the 
polymer was determined by the ratio of initiator used in the polymerisation reaction. It ranged from 10 
to 50 repeating units, with an average of 20, for the different polymers synthesised, depending on the 
monomer(s) used. As the number of peptide copies, in applications exploiting polyvalent interactions 
of peptide sequences, vary according to the different candidate sequences, no general length of the 
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polymer backbone can be predetermined. The length of the polymers obtained here, allowing the 
conjugation of up to 20 peptide copies on average was deemed suitable for the application targeted [17]. 
They were purified by Size-Exclusion Chromatography (SEC) using Sephadex LH20 to remove 
byproducts and analysed by 1H-NMR, MALDI-TOF MS and analytical RP-HPLC where possible. 
For the peptide candidates, two sequences containing representative guanidino-, hydroxyl- and 
carboxyl-, or its amidated counterpart, side-chain functionalised residues were selected for initial 
conjugation assays. They were a pentapeptide (GRGDS) containing the RGD integrin-recognition 
motif and a hexapeptide bearing the extracellular amino-terminal domain (SFLLRN, also known as 
TRAP1–6) of the Protease-activated Receptor-1 (PAR-1), a platelet receptor for thrombin [18]. A third 
sequence, GWYRGRL, a collagen IIα1 binding peptide, was also chosen for complementary assays, to 
test the conjugation chemistry in the presence of amino acids with phenolic and indolic side-chains. 
2.1. Homo- and Co-Polymers of Allyl Glycidyl Ether and Their Functionalisation by the  
Thiol-Ene Reaction 
PAGE was synthesized by anionic polymerisation, using potassium tert-butoxide as initiator, as 
shown in Scheme 1. 
Scheme 1. Synthesis of poly(allyl glycidyl ether) (1) by anionic polymerisation. 
 
Preliminary conjugation assays showed that the selected peptide sequences (RGD and TRAP1-6) 
could be successfully conjugated to this homopolymer by a thiol-ene reaction. The PAGE-TRAP1-6 
conjugate was poorly soluble in aqueous buffers, therefore, poly(ethylene glycol-co-allyl glycidyl 
ether) co-polymers (P(EO-co-AGE)), expected to have greater solubility in water, were prepared by 
using ethylene carbonate and allyl glycidyl ether as monomers. At that time, P(EO-co-AGE)s were 
independently reported as PEG derivatives with high loading capacities for amino acids and peptides [16]. 
We were also aware of one limitation of the thiol-ene chemistry encountered during the conjugation of 
the collagen binding peptide to PAGE, restricting its application to sequences devoid of tyrosine 
residues and limiting therefore its versatility. The phenolic side-chain of tyrosine can indeed act as a 
radical scavenger during the thiol-ene reaction, as evidenced by the failure to conjugate GWYRGRL. 
The reaction was repeated with individual, side-chain functionalised amino acids not present in 
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TRAP1–6, namely tyrosine and tryptophan. In the former case, no thiol-ene reaction took place. This is 
not unexpected, as phenolic groups can be exploited in radical scavengers such as monomethylether 
hydroquinone (MEHQ), as shown in Scheme 2. 
Scheme 2. Mechanism of MEHQ quenching of a thiol-radical [19]. 
 
Beside this limitation, the use of a proteinogenic amino acid as one of the partners in the thiol-ene 
conjugation precludes the presence of free cysteines in the sequence of the bioactive peptide. 
Additionally, it requires, for heterodetic peptides, the formation of the disulfide bridge(s) and the use 
of an orthogonally protected cysteine prior to the conjugation step. This could limit the yield of the 
peptide available for conjugation, when an excess of peptidic reagent is actually required for this reaction. 
We therefore investigated alternative conjugation strategies, initially focusing on the copper(I)-catalysed 
azide-alkyne cyclo-addition, owing to its success in efficient and selective modifications of complex 
natural macromolecules [20–23]. Two possible approaches, where the polymer and the peptide were 
either assigned the role of alkyne or azide partners respectively, were evaluated. We also evaluated an 
amine-functionalised polymer to provide an alternative route of peptide coupling based on direct amide 
bond formation. 
2.2. PEG Derivatives for Multiple Conjugation of Peptides by Azide-Alkyne Cycloaddition 
2.2.1. Alkynylated Polymer and Azido-Peptide 
PAGE can also be synthesised by cationic polymerisation and subsequently modified by functional 
group interconversion. According to this approach, PAGE was first deprotected to give polyglycerol, 
using palladium over charcoal following previously published methods [24]. Conversion from polyglycerol 
to poly(propargyl glycidyl ether) was then performed by alkylation with propargyl bromide, as shown 
in Scheme 3. 
Poly(allyl glycidyl ether) (2) was obtained in 95% yield from the starting monomer. Full removal of 
allyl protecting groups was possible, however only 50% of the polymer product was recovered 
following allyl deprotection. Poly(propargyl glycidyl ether) (4) was synthesised with a yield of 15% 
following purification by SEC through Sephadex LH20. 
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Scheme 3. Synthesis of poly(allyl glycidyl ether) (2) and conversion to poly(propargyl 
glycidyl ether) (4).  
 
Reagents and conditions: (a) Triphenylcarbenium hexafluorophosphate (0.05 eq.), 0 °C, 12 h;  
(b) p-toluenesulfonic acid (0.1 eq.), 10% Pd/C (40 mg/mmol), reflux, 24 h; (c) propargyl bromide 
(80% in toluene, 1.8 mmol), NaH, RT, 12 h. 
In parallel, two RGD peptide amides were synthesised manually by Solid Phase Peptide Synthesis 
(SPPS) [16] using the Fmoc/t-Bu strategy [25,26], with either an additional N-terminal azido glycine, 
N3-GGRGD 5 (Figure 1), or no N-terminal modification, GRGDS 6 (Figure 2). Following cleavage 
from the resin, these peptides were purified by RP-HPLC and analysed by RP- and SEC-HPLC. 
Compound 5 was intended as the azide partner in the click chemistry reaction with the alkyne polymer 
4. The azido functionality was introduced on the resin-bound peptide by converting its N-terminus 
from amino to azido by reaction with imidazole-1-sulfuryl azide hydrochloride, according to a 
published procedure applicable to all coded amino acids [27]. Peptide 6 was synthesised as a control 
peptide sequence for biological testing. 
Figure 1. N3-GGRGD-NH2. 
 
Figure 2. H-GRGDS-NH2. 
 
The cyclo-addition reaction of 4 and 5 was next attempted in the presence of a copper(I) catalyst 
generated in situ from copper sulfate and sodium ascorbate as a reducing agent, and using water and 
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tert-butanol as cosolvents (Scheme 4). However, no triazole product, and therefore no conjugation of 
the peptide on the modified PEG backbone, was obtained under these conditions, as indicated by 
analysis of the MALDI-TOF MS results. The reaction of polymer 4 with a simpler azide, (2S)-2-azido-3-
methylbutanoic acid, was also attempted under the same conditions. Following purification by SEC 
using Sephadex LH-20, the product was analysed by 13C NMR, but no signal characteristic of the 
triazole ring could be observed in its spectrum. This absence of conversion is unexpected as the  
azide-alkyne cyclo-addition has been successfully used in a number of challenging applications, 
including polymer chemistry. While the short PEG derivatives produced here could maybe complex 
the copper, in an analogous manner than crown ethers, this would not explain a complete absence of 
catalysis, as some conversion is observed when the azide and alkyne partners are inverted (vide infra). 
As no reaction is obtained, even with (2S)-2-azido-3-methylbutanoic acid, it is unlikely that this lack of 
reaction is (solely) due to a reduction of the peptidic azide before conjugation which can occur upon 
storage of this reagent. This suggests that the reaction deficiency could originate from poly(propargyl 
glycidyl ether), although the analytical results obtained for this polymer indicated its integrity. 
Scheme 4. Conjugation attempt of an azido RGD peptide (5) with poly(propargyl glycidyl 
ether) (4) in the presence of CuSO4·5H2O (0.045 eq.), sodium ascorbate (0.045 eq.),  
water:t-butanol (1:1), RT, 48 h.  
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2.2.2. Azido-Polymer and Alkynylated Peptide 
Another polymer synthesised for peptide conjugation by azide-alkyne cycloaddition was 
poly(glycidyl azide) (9). Synthesis of polyepichlorohydrin (8) by cationic polymerisation, followed by 
reaction with sodium azide provided this polymeric azide reagent. Quantitative conversion to 
poly(glycidyl azide) (9) took place, with 50% yield of polymer recovered (Scheme 5). 
Scheme 5. Synthesis of poly(glycidyl azide) (9). 
 
Reagents and conditions: (a) Triphenylcarbenium hexafluorophosphate (0.05 eq.), 0 °C, 12 h;  
(b) sodium azide (1.5 eq.), 100 °C, 12 h. 
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In parallel, synthesis of an alkynylated collagen-binding peptide was carried out by coupling 
propiolic acid at the N-terminus of the GWYRGRL sequence 10 (Figure 3), using HATU and DIEA [28]. 
The amide bond formation was monitored by the Kaiser test. The coupling reaction and subsequent 
cleavage of the alkynylated peptide from the resin were completed in darkness. The later step was 
performed with a cleavage cocktail consisting of TFA (95% v/v), with triisopropylsilane and water as 
scavengers (2.5% v/v each), for 90 min, as described for these modified peptides [28]. However, 
relatively low yields of alkynylated peptide were obtained after purification, the major product being 
the unmodified peptide. It is possible that the acidity of the terminal alkyne interferes in the coupling 
reaction performed in the presence of an excess of DIEA. The use of a protected alkyne was therefore 
investigated to couple the alkyne. However, the reaction performed with trimethylsilane-protected 
propiolic acid gave similar yields. In addition, complete removal of the TMS group did not occur 
during cleavage, despite its high susceptibility to water. 
Figure 3. Propiolyl-GWYRGRL-NH2. 
 
Conjugation of the alkyne-modified peptide and polyglycidyl azide was attempted through copper 
catalysed cycloaddition. Copper sulfate and sodium ascorbate, the most successful reagents 
documented for this click chemistry, were again selected for the generation of the catalyst. Following 
conjugation, purification by SEC on Sephadex LH20 was carried out. The reaction shown in Scheme 6 
provided a small amount of conjugated product, as evidenced by MALDI-TOF MS analysis which 
indicated that up to two peptide units had been attached to the polymer backbone. 
Scheme 6. Conjugation of an alkynylated peptide 10 with polyglycidyl azide (9) in the 
presence of CuSO4·5H2O (0.045 eq.), sodium ascorbate (0.045 eq.), water:t-butanol (1:1),  
RT, 48 h. 
 
However, the complete purification of the conjugate obtained remained impracticable, all samples 
obtained being contaminated by copper traces, as confirmed by the blue/green colour of their solutions. 
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2.3. PEG Derivatives for Multiple Conjugation of Peptides by Amide Linkage 
Synthesis of Poly(Glycidyl Amine) 
Utilising an amide coupling reaction would be the simplest method to conjugate a peptide to the 
polymer chain, exploiting either a free N- or C-terminus, despite the limitations imposed on the peptide 
content related to lysine, or aspartic and glutamic acids, respectively. In this instance, the polymer, 
conversely, would require carboxylic acid or amine functional groups. Through anionic polymerisation 
of an amine functionalised epoxide and subsequent deprotection, poly(glycidyl amine) (13) was 
successfully prepared, as shown in Scheme 7. 
Scheme 7. Synthesis of poly(glycidyl amine) (13). 
 
Reagents and conditions: (a) KOtBu, 145 °C, 20 min, (b) TFA: DCM 55:45, RT, 2 h. 
This was conjugated to a peptide amide with a free carboxylic acid (Ac-GWYRGRLE) 14 (Figure 4).  
An additional C-terminal glutamic acid was added onto the peptide chain to permit conjugation from 
its γ-carboxyl, as presented in Scheme 8. 
Figure 4. Ac-GWYRGRLE-NH2.  
 
Purification by SEC was carried out on Sephadex G-25 and the product was analysed by  
SEC-HPLC and MALDI-TOF MS. The chromatogram obtained indicated that the coupling reaction 
had taken place, as evidenced by a new broad signal at lower retention time than the narrow signal 
corresponding to the peptide alone. From the MALDI-TOF MS, it was determined that a maximum of 
two peptide chains were attached. 
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Scheme 8. Coupling of poly(glycidyl amine) (13) to peptide (14).  
 
Reagents and conditions: EDC (2 mM), NHS (5 mM) at pH 7.5, 12 h. 
2.4. PEG Derivatives for Multiple Conjugations of Peptides by the Thiol-Ene Reaction 
2.4.1. Synthesis 
Having investigated alternative coupling chemistries for the loading of peptides on a PEG 
backbone, we compared their performances to those achieved with the thiol-ene reaction. The RGD 
peptide amide was synthesised manually and elongated with a N-terminal cysteine. The conjugation 
reaction was carried out under UV light with dimethyoxyphenylacetophenone (DMPA) as initiator 
(Scheme 9) and analysed by SEC-HPLC and MALDI-TOF MS. The former technique confirmed the 
presence of conjugates, larger than the peptide alone and its dimer. 
Scheme 9. Conjugation of H-CGRGDS-NH2 16 (Figure 5) and poly(allyl glycidyl ether) 
(1) in the presence of DMPA (1 eq.), in DCM under UV light (365 nm), at room 
temperature, during 48 h.  
 
Figure 5. H-CGRGDS-NH2.  
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Following purification by SEC using Sephadex LH-20, MALDI-TOF MS analysis of the product 
indicated that a polydisperse conjugate containing up to two peptide units had been obtained and that it 
could be tested in biological assays. This suboptimal multivalency of the peptide ligand, also affecting 
the previous polymer-peptide conjugates prepared, could originate from the steric hindrance exerted 
within the functional homopolymer. The formation of peptide homodimers, favoured over the 
heterodimers formed during conjugation to the polymer, could also impact on the efficiency of the 
latter reaction. While it can be implemented with an excess of peptide, the number of equivalents of 
this reagent remains in practice limited by its cost. 
2.4.2. Biological Testing 
Beside its binding to the αvβ3 integrin and therefore its function in the targeting of imaging or 
therapeutic agents to the tumour vasculature, the RGD (Arg-Gly-Asp) peptide motif is present in 
plasma fibrinogen and other adhesive proteins and it is recognised by glycoprotein IIb/IIIa (αIIbβ3) on 
the platelet plasma membrane [29]. Preventing the binding of fibrinogen to αIIbβ3 causes inhibition of 
platelet aggregation and subsequent thrombus formation. The RGD motif has also been used in 
research to mimic cell-adhesion proteins [30,31]. These can be on surfaces, to promote adhesion, or 
may be used in solution, acting as decoys and preventing adhesion in anti-thrombotic therapies [31]. 
For the studies reported here, various concentrations of peptides were examined for their ability to 
inhibit platelet aggregation in TRAP-stimulated platelets. The peptides were dissolved in 5% ethanol 
in water, as they did not fully dissolve in water alone. Both the polymeric and free peptides were 
effective inhibitors of platelet aggregation. In addition, both acted in a dose-dependent manner as 
anticipated (Figure 6).  
Figure 6. Human washed platelets (300 × 103 platelets/μL) were incubated with increasing 
concentrations (0.5, 2, 5, 20 and 50 μM) of the free (light trace) or polymeric (dark trace) 
for 5 min at 37 °C in stirring conditions. Following stimulation with TRAP (4 μM), 
platelets were assayed for aggregation in light transmission aggregometry. The data are 
Mean ± SEM of two independent experiments.  
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At a dose of 20 μM the PAGE-RGD conjugate inhibited platelet activation at a lower, albeit not 
significant, extent when compared with the free peptide. However, when the concentration of the  
PAGE-RGD conjugate was increased to 50 μM, the platelet aggregation response was completely 
ablated. Due to solubility problems with the free peptide, it was not possible to test it at 50 μM, thus, 
Abciximab (Abx, 50 μM), a specific therapeutic chimeric monoclonal blocking antibody against αIIbβ3, 
was employed as a positive control of the inhibitory effect. The solvent (5% ethanol/water) was also 
ran as a vehicle control to confirm platelet viability and it did not affect aggregation in this study (data 
not shown). 
3. Experimental Section 
3.1. General Experimental Procedures 
Solvents and reagents were purchased from commercial suppliers (Sigma-Aldrich, Wicklow, 
Ireland; Acros, Dublin, Ireland; Lennox, Dublin, Ireland; and VWR, Dublin, Ireland) and used without 
further purification unless otherwise stated. 1H-NMR spectra were recorded at 400 MHz and 13C-NMR 
spectra at 100.6 MHz on a Bruker Avance 400 spectrometer (Bruker UK Ltd., Coventry, UK). 
Samples were prepared in CDCl3, D2O, MeOD and DMSO-d6, with these solvent peaks providing 
internal standards. Chemical shifts (δH) are quoted in parts per million (ppm). Coupling constants (J) 
are in Hertz and corrected to the nearest 0.5 Hz. Multiplicities are denoted by s (singlet), d (doublet), t 
(triplet), q (quartet), dd (double of doublets), m (multiplets), br (broad), bb (polymer backbone).  
1H, 13C data are included for each compound, where appropriate. MALDI-TOF MS for relevant 
samples were obtained on an AB Sciex 4800 MALDI-TOF/TOF (AB Sciex UK Ltd., Cheshire, UK), 
using α-cyano-4-hydroxycinnamic acid (CHCA) as a matrix. 
Purification of polymers and conjugates were carried out by SEC using Sephadex LH20 or G25. 
Sephadex LH20 was run with methanol as a solvent, while Sephadex G25 used water as a solvent. 
TLC plates were visualised with iodine, ninhydrin or UV fluorescence at the appropriate wavelengths. 
Analysis of conjugates by SEC was carried out on Varian HPLC Perfusion Chromatography 
Workstation (Agilent Technologies, Santa Clara, CA, USA) using a Phenomenex BioSep 2000 
column. Solvent A was phosphate buffer (0.25 M K2HPO4 and 0.25 M KH2PO4) at pH 6 and solvent B 
was acetonitrile, used at an isocratic elution (50:50) over 45 min. 
3.2. Polymer Synthesis 
Anionic-polymerisation of poly(allyl glycidyl ether) (1). Potassium tert-butoxide (24.5 mg, 0.22 mmol, 
1 eq.) and sodium hydride (60% dispersed in mineral oil, 41 mg, 0.22 mmol, 1 eq.) were stirred at 
room temperature under argon for 1 h. Allyl glycidyl ether (500 mg, 4.39 mmol, 20 eq.) was then 
added and heated neat at 120 °C for 24 h. Poly(allyl glycidyl ether) (444 mg, 3.89 mmol, 88% yield) 
was recovered as a viscous yellow-brown gel. 1H-NMR (CDCl3) δ = 5.85 (m, 1H, OCH2CH=CH2), 
5.28–5.14 (2H, dd, OCH2CH=CH2), 3.90 (d, 2H), 3.37–3.33 (m, 5H) 13C-NMR (CDCl3) δ = 134.78 
(OCH2CH=CH2), 117.04 (OCH2CH=CH2), 79.20 (CH backbone), 72.25 (OCH2CH=CH2), 70.11 (CH2 
backbone), 69.54(CH2 backbone). MALDI-TOF MS m/z: repeating unit found 114.0671; requires 
114.0681; Δ = 9 ppm. 
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Cationic-polymerisation of poly(allyl glycidyl ether) (2). Triphenylcarbenium hexafluorophosphate  
(85 mg, 0.22 mmol, 0.05 eq.) was dissolved in anhydrous dichloromethane (5 mL) and added dropwise 
to a solution of allyl glycidyl ether (500 mg, 4.39 mmol, 1 eq.) in dichloromethane (20 mL), cooled to 0 °C. 
After 12 h stirring, the reaction was quenched with methanol and the solvent evaporated to give 
poly(allyl glycidyl ether). Poly(allyl glycidyl ether) is a viscous yellow-orange gel, obtained in 95% 
yield (650 mg, 4.19 mmol). NMR analysis determined the polymer to have an average of 22 units.  
1H-NMR (CDCl3) δ = 7.23 (6H, m-Ph), 7.15 (3H, p-Ph), 7.05 (6H, o-Ph), 5.85 (m, 22H, 
OCH2CH=CH2), 5.28–5.14 (44H, dd, OCH2CH=CH2), 3.90 (d, 44H, OCH2CH=CH2), 3.63–3.34 (m, 
110H, OCH2CH(CH2R)O) 13C-NMR (CDCl3) δ = 143. 89 (CR4), 134.84 (OCH2CH=CH2), 130.07 (6C), 
128.29 (6C), 126.29 (3C), 117.40 (OCH2CH=CH2), 79.20 (CH backbone), 72.25 (OCH2CH=CH2), 
70.11 (CH2 backbone), 69.54 (CH2 backbone); MALDI-TOF MS m/z: repeating unit found 114.0671; 
requires 114.0681; Δ = 9 ppm. 
Polyglycerol (3). To a solution of poly(allyl glycidyl ether) (1, 1.68 g, 15 mmol) in methanol (50 mL), 
p-toluenesulfonic acid (285 mg, 1.5 mmol) followed by 10% Pd/C (600 mg, 40 mg per mmol) were 
added. The solution was refluxed for 24 h. It was then cooled, filtered through a celite plug and rinsed 
with methanol. The sample was concentrated, redissolved in minimum volume of methanol and the 
polymer was precipitated with cold diethyl ether. 1.145 g of polymer was recovered as a viscous 
yellow gel (50% yield). 1H-NMR (CDCl3) δ = 3.65–3.56 (m, 3H), 3.54–3.47 (m, 2H) 13C-NMR 
(CDCl3) δ = 79.69 (br, CH2), 68.86 (br, CH), 60.62 (br, CH2); MALDI-TOF MS m/z: repeating unit 
found 74.0282 average; requires 74.0368; Δ = 115 ppm. 
Poly(propargyl glycidyl ether) (4). Polyglycerol (3, 74 mg, 1 mmol) was dissolved in DMF (1.5 mL) 
under nitrogen. Sodium hydride, 60% solution dispersed in mineral oil (40 mg, 1 mmol) was added 
and the solution stirred at room temperature for 30 min. Propargyl bromide, 80% solution in toluene 
(148 mg, 111 μL, 1 mmol) was added and the solution stirred at room temperature overnight. Water 
(40 mL) was added, the resulting solution acidified and product was extracted with ether (3 × 15 mL). 
21 mg (18% yield) of a thick yellow gel was recovered. 1H-NMR (CDCl3) δ = 4.14 (s, 2H, 
OCH2CCH), 3.65–3.45 (m, 5H, OCH2CH(CH2OR)O), 2.40 (1H, OCH2CCH) 13C-NMR (CDCl3)  
δ = 79.88 (CH2CCH), 78.58 (CH2CCH), 76.59 (CH2OCH2CCH), 74.73 (CH(CH2OR)), 69.74 
(CH2CH(CH2OR)), 58.59 (CH2CCH); MALDI-TOF MS m/z: repeating unit found 112.0497; requires 
112.0524; Δ = 24 ppm. 
Poly(epichlorohydrin) (8). Epichlorohydrin (1.24 g, 13.5 mmol) was cooled to 0°C. Triphenylcarbenium 
hexafluorophosphate (133 mg, 0.343 mmol) was dissolved in anhydrous DCM (4 mL) and cooled. 
This solution was added to the cooled epichlorohydrin over 5 min. It was stirred at room temperature 
overnight and precipitated with methanol. After centrifuging the solution, a clear gel is formed. This is 
dried under vacuum to yield poly(epichlorohydrin) as a clear gel (744 mg, 62% yield). NMR analysis 
determines the polymer to have an average length of 38 units. 1H-NMR (CDCl3) δ = 7.26 (m, Ph3), 
3.62 (m, 39H), 3.64–3.53 (m, 26H) 13C-NMR (CDCl3) δ = 126.92 (Ph3), 78.08(br, CH2CHO), 69.45 
(br, CH2CHO), 42.52 (br, CH2Cl); MALDI-TOF MS m/z: rRepeating unit found: 92.005; requires 
92.003; Δ = 22 ppm. 
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Poly(glycidyl azide) (9). Poly(epichlorohydrin) (250 mg, 2.72 mmol) was dissolved in DMF (1 mL). 
Sodium azide (211 mg, 3.25 mmol) was added and the solution was stirred at 100 °C for 12 h. Water 
(1 mL) was added dropwise after cooling to room temperature and the polymer precipitated out. The 
gel obtained after centrifuging was dried under vacuum to yield a viscous yellow gel (134 mg, 50% 
yield). NMR analysis determines the polymer to have an average length of 46 units. 1H-NMR (CDCl3) 
δ = 7.22 (m, Ph3), 3.30 (m, 150H), 3.25 (m, 93H) 13C-NMR (CDCl3) δ = 127.92 (Ph3), 78.81 (br, 
CH2CHO), 70.77 (br, CH2CHO), 52.30 (br, CH2N3); MALDI-TOF MS m/z: repeating unit found 
99.042; requires 99.043; Δ = 10 ppm. 
Poly(glycidyl tert-butyl carbamate) (12). To oxiranylmethyl-carbamic acid-tert-butyl ester (430 mg, 
2.49 mmol), potassium tert-butoxide (14 mg, 0.124 mmol) was added neat under nitrogen and the 
solution was stirred at 145 °C for 20 min. When the polymer had begun to solidify the polymerisation 
was quenched by adding methanol (2 mL). The solvent was removed under vacuum and 406 mg of 
product was obtained (94% yield) as a viscous brown gel. NMR analysis, based on the tert-butyl group 
signal determines the polymer to have an average length of 12 units. 1H-NMR (CDCl3) δ = 3.68–3.23 
(m, 60H), 1.37 (s, 108H, 3CH3) 1.11 (s, 9H, 3CH3 t-Bu) 13C-NMR (CDCl3) δ = 158.5 (br, C=O), 78.6 
(br, CH), 69.3 (br, CH2), 40.6 (br, CH2), 28.34 (3CH3), 27.56 (t-Bu initiator);  MALDI-TOF MS m/z: 
Not obtained as polymer was not readily ionized. 
Poly(glycidyl amine) (13). Amine deprotection was carried out by dissolving the polymer (400 mg,  
2.3 mmol) in dichloromethane (2 mL) and trifluoroacetic acid (2 mL). This was stirred at 0 °C for 30 min 
followed by heating to room temperature for 2 h with no stopper on the flask. The solvent was then 
evaporated under nitrogen gas, the residue dissolved in water and freeze dried to remove residual acid. 
A viscous yellow gel was recovered in 100% yield. 1H-NMR (CDCl3) δ = 3.74–3.53 (br, 36H), 3.33–3.05 
(br, 24H), 1.11 (s, 9H, 3CH3 t-Bu) 13C-NMR (CDCl3) δ = 75.14 (m, CH), 67.84 (m, CH2), 41.49 (m, 
CH2); MALDI-TOF MS m/z: repeating unit found average 73.0483; requires 73.0528; Δ = 61 ppm. 
3.3. General Procedure for Peptide Syntheses 
Peptide sequences were assembled manually by SPPS using a fritted syringe. 1 mmol (10 fold 
molar excess) quantities of each protected amino acid were used. The amine group on the resin is 
Fmoc protected initially but is available for amino acid coupling at the start of the synthesis, as a result 
of piperidine (20% in NMP) deprotection. The peptide was elongated from the C-terminus (amide 
functional group) to the N-terminus (amino group). 
Following assembly and modification of the sequence, when relevant, the peptide was cleaved from 
the resin and deprotected of its semi-permanent groups. Generally the following mixture was added to 
the dried resin with a magnetic stirrer: Trifluoroacetic acid (95%), triisopropylsilane (2.5%), water 
(2.5%), the reaction was stirred gently for 2.5 h. The solution was then filtered and the peptide 
precipitated from the filtrate with chilled diethyl ether, followed by isolation of the precipitate by 
centrifugation (5 min × 2.8 × 103 rpm). The liquid phase was discarded and the peptide washed with 
ether twice more. The peptide was finally solubilised in water and lyophilised on an EC Modulyo-230 
freeze dryer (Fischer Scientific Ireland, Dublin, Ireland). 
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Peptides were purified by Reverse-Phase HPLC on a PerSeptive Biosystems BioCAD SPRINT 
(Life Technologies, Warrington, UK) system using a semi preparative column Gemini C-18 reverse-phase 
chromatography obtained from Phenomenex (Phenomenex, Macclesfield, UK). The Gemini C 18  
(250 mm × 10 mm) column was used at 5 mL/min on a linear gradient program from 5% to 65% 
solvent B. Solvent A was water (0.1% TFA) and solvent B was acetonitrile (0.1% TFA). UV 
monitoring was performed at 214 nm unless otherwise stated. Analysis of peptides was carried out by 
Reverse-Phase HPLC on a Varian HPLC Chromatography Workstation (Agilent Technologies,  
Santa Clara, CA, USA) using the same solvent system as above, at 1 mL/min. 
N3-GGRGD-NH2 (5). Following assembly of peptide sequence GGRGD by SPPS as described above, 
the terminal amine was converted to N3 with imidazole-1-sulfonyl azide hydrochloride (3 eq.), DIEA 
(4.5 eq.) in DMF. After stirring for 90 min, a Kaiser test determined incomplete coupling and the 
reaction was repeated with fresh reagents. MALDI-TOF MS m/z: found 486.148; requires 485.206. A 
purity of 82% was determined by RP-HPLC (C18). 
H-GRGDS-NH2 (6). Prepared as described above. MALDI-TOF MS m/z: found 490.48; requires 
489.47. RP-HPLC (C18) shows purity of 93%. 
Propiolyl-GWYRGRL-NH2 (10). Following assembly of the peptide sequence GWYRGRL by SPPS as 
described above, propiolic acid (5 eq.), HATU (4.9 eq.) and DIEA (12 eq.) were added to the 
deprotected peptide on resin. As the propiolic is light sensitive, the coupling reaction was completed in 
the dark for 120 min. The peptide was then cleaved and purified as described above. MALDI-TOF and 
ESI-MS both confirmed the successful synthesis of this peptide. ESI MS m/z: found [M+H]+1 958.46; 
requires 957.50. A purity of 97% was determined by RP-HPLC (C18). 
Ac-GWYRGRLE-NH2 (14). Prepared as described above. MALDI-TOF MS m/z: found 1077.54; 
requires 1077.21.RP-HPLC (C18) shows purity of this peptide to be 98%. 
H-CGRGDS-NH2 (16). Prepared as described above. MALDI-TOF MS: m/z: found 593.199; requires 
592.63. RP-HPLC (C18) shows purity of 70%. 
3.4. Conjugations 
3.4.1. Cycloaddition Product 7  
Poly(propargyl glycidyl ether) (4, 6.1 mg, 1 eq.) was dissolved in t-butanol (0.5 mL) and  
N3-GGRGD-NH2 (5, 53 mg, 2 eq.) was added in water (0.3 mL). CuSO4.5H2O (6.1 mg, 0.045 eq.) and 
sodium ascorbate (4.85 mg, 0.45 eq.) were dissolved in water (1 mL each) and 100 μL of each was 
added to the solution. The resulting mixture was stirred for 48 h at room temperature. MALDI-TOF 
MS did not give the correct mass for the conjugated product. This conjugation was not considered to  
be successful. 
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3.4.2. Cycloaddition Product 11 
Poly(glycidyl azide) (9, 3.76 mg, 2 eq.) and propiolyl-GWYRYGL-NH2 (10, 18 mg, 1 eq.) were 
dissolved in tert-butanol (500 μL) and water (300 μL). Sodium ascorbate (198 mg in 1 mL) and 
CuSO4·5H2O (45 mg in 1 mL) solutions were prepared fresh and 100 μL of each was added to the 
polymer-peptide solution. This was stirred at 30 °C overnight over which period the suspension 
cleared. The solvent was evaporated and NMR and size exclusion chromatography carried out. 
MALDI-TOF MS analysis indicated that up to two units of peptide were attached. 
3.4.3. Amide Linkage Conjugated Product 15  
Ac-GWYRGRLE-NH2 (14, 11 mg, 0.01 mmol) was dissolved in 2-(N-morpholino)ethanesulfonic 
acid buffer (0.5 mL) and NHS (10 mg) and EDC (16 mg) were added. The solution was stirred at room 
temperature for 30 min. Poly(glycidyl amine) (13, 0.6 mg, 0.008 mmol) was dissolved in PBS buffer  
(0.5 mL). It was added to the solution which was stirred overnight. The mixture was purified by 
Sephadex G-25 and the fractions containing some product as determined by iodine staining were 
freeze dried. SEC-HPLC and MALDI-TOF MS analyses indicated that the peptide had coupled to the 
polymer, up to two peptide units per chain. Approximately 1 mg (0.0004 mmol) was recovered, 5% yield. 
3.4.4. Thiol-Ene Conjugation Product 17  
To a solution of poly(allyl glycidyl ether) (1, 308 mg, 2.7 mmol) in dry DCM (2 mL) in a clear vial, 
H-CGRGDS-NH2 (16, 2 eq.) was added in dry methanol (1 mL). 2,2-Dimethoxy-acetophenone  
(300 mg) was added and stirred under UV light at 365 nm for 48 h. The solvents were evaporated and 
the conjugate was purified on a Sephadex LH-20 column, eluted with methanol. The conjugate was 
analysed by NMR, MALDI-TOF MS and SEC-HPLC (Biosep S2000, Phenomenex, Cheshire, UK,  
300 mm × 7.8 mm, 5 μm). 
3.5. Biological Assays 
3.5.1. Platelet Isolation 
Washed platelets (WP) were prepared from donors who gave informed consent and declared that 
they were medication free for the previous 10 days. Venous blood was drawn into 15% (v/v) of  
acidcitrate-dextrose (ACD) anticoagulant (38 mM citric acid anhydrous, 75 mM sodium citrate, 124 mM 
dextrose). Blood was centrifuged at 150× g for 10 min at room temperature and the supernatant platelet 
rich plasma (PRP) was collected. PRP was acidified with ACD at pH 6.5 and 1 mM prostaglandin E1 
(PGE1) was added. The platelets were pelleted 720× g for 10 min and resuspended in buffer (6 mM 
dextrose, 130 mM NaCl, 9 mM NaHCO3, 10 mM sodium citrate, 10 mM Tris base, 3 mM KCl, 0.81 mM 
KH2PO4 and 0.9 mM MgCl2·6H2O, pH 7.35) and the concentration adjusted to 3 × 105 platelets/mL. 
Washed platelets were supplemented with 1.8 mM CaCl2. 
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3.5.2. Platelets Adhesion Assay 
Plates (96 transparent flat bottom wells) were coated with fibrinogen (10 mg/mL) 100 μg/mL in 
phosphate buffered saline (PBS), for 2 h at 37 °C. Nonreactive sites were blocked with bovine serum 
albumin (BSA 2 mg/mL, 5% in PBS) (1 h and 30 min, 37 °C). Wells were washed twice with 100 μL 
of JNL Buffer and exposed to platelets. Control surfaces were coated with albumin BSA. Platelets (50 μL, 
3 × 105 platelets/mL) were pre-treated with polymer-conjugated RGD peptide (50 μM, 20 μM), 
monomer RGD peptide (20 μM), Abciximab (Abx, 50 μg/mL) or vehicle control before seeding in 
each respective well and allowed to adhere for 40 min at 37 °C. Non-adherent platelets were removed, 
and the wells were rinsed three times with 200 μL of JNL Buffer. The remaining cells were allowed to 
react with p-nitro phenol phosphate (PnPP) solution (0.1 M sodium acetate, 0.1% Triton X-100)  
for 90 min at 37 °C. The reaction was quenched by adding 20 μL of sodium hydroxide (NaOH, 1 M) to 
each well. Adherent platelets were quantified on a Wallac reader at 405 nm. Experiments were 
repeated at least three times. 
3.5.3. Platelet Aggregation Assay 
Platelet aggregations were performed at 37 °C in a BioData PAP-4 aggregometer (Horsham, PA, 
USA). Briefly, 200 µL of washed platelets (250 × 103/µL) were stirred at 37 °C for 2 min, followed by 
addition of TRAP (SFLLRN; 4 μM) for a further 20 min. To study the effect of peptides, platelets were 
pre-incubated for 5 min with polymer-conjugate RGD peptide (50 μM, 20 μM) or monomeric RGD 
peptide (20 μM). Abx (2 mg/mL) was used as positive control and water 5% ethanol as vehicle control. 
Experiments were repeated at least twice. 
4. Conclusions 
The platelet aggregation study performed with a PEG derivative modified with a synthetic peptide 
suggests that both the free peptide and its polymeric counterpart can inhibit platelet adhesion. While 
the efficiency of the polymeric-RGD doesn’t exceed in these studies the efficiency of the monomeric 
peptide, it is important to remember that in a biological system it is possible that this unsurpassed 
efficiency may still be offset by the increased stability and circulation time of a polymer conjugate [32]. 
Therefore, further studies to demonstrate the applicability of the polymeric RGD peptide should 
examine for example its proteolytic stability in plasma and blood. 
Another important factor in these studies is the solubility of these peptides. Both free and  
polymeric-RGD suffer from low water solubility and were dissolved in 5% ethanol in water, but the 
peptide still benefits from the conjugation to the polymer backbone. Altering the peptide sequence to 
include more hydrophilic residues may be of benefit, as would the deprotection of unconjugated allyl 
groups on the polymer chain, to give water-soluble polyglycerol units along the backbone. 
PEG derivatives with high peptide loading capacities are not only potential nanomedicines, but can 
also find applications as targeted drug delivery systems, by using homing peptides, or polymeric 
prodrugs, by using protease-dependent peptide linkers. The conjugation chemistry and its efficiency 
will determine the synthetic strategy for the generation of these candidates and its applicability.  
The results of the conjugation assays reported here show that the thiol-ene reaction and azide-alkyne 
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cyclo-addition can be implemented, but that some limitations may apply. In both cases, the number of 
peptide chains appended to the polymer chain is low, approximately 1 peptide for every 10 repeating 
units, but this could be due to the steric hindrance exerted between adjoining functional groups for 
conjugation in a homopolymer. This limitation could be addressed by the use of co-polymers such as 
P(EO-co-AGE) or their derivatives obtained by deprotection of the allyl groups and functional group 
interconversion, as reported here. Both homo- and co-polymers obtained by these approaches have an 
average molar mass significantly lower than conventional linear PEGs, but it is possible to use one 
such PEG as an initiator of anionic polymerisation of allyl glycidyl ether, as successfully performed in 
our studies with a MeO-PEG-OH of average molar mass of 1000 g/mol. 
Conjugation chemistries capable of selectively and efficiently loading multiple copies of a peptide 
to an appropriately functionalised polymeric backbone are not limited to the ones reported here. For 
example, polyglycerol obtained by allyl deprotection of PAGE can potentially be used for imine-type 
conjugation chemistries, by oxidation of the polymer’s hydroxyl groups and the use of an oxime- or 
hydrazide- modified peptide. However, preliminary assays completed during our studies indicated that 
the polyglycerol remained refractory to oxidation under common conditions, including reagents such 
as potassium permanganate. 
In conclusion, the thiol-ene reaction, despite a restriction in the peptide content limited to tyrosine, 
is a promising chemistry for the conjugation of peptides to polymeric and other macromolecular 
materials, owing to the simple scale-up of the peptide synthesis phase, the ease of execution of the 
conjugation step and the uncomplicated purification of the conjugates produced. 
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